Cancer Therapies (Drug Resistance)

Phase I/II Resistance Trial Begins with Encapsulated Doxorubicin

Published in Cancer Weekly, June 30th, 1997

NeoPharm, Inc., Lake Forest, Illinois, reported that it has begun a Phase I/II clinical trial with Liposome Encapsulated Doxorubicin (LED).

The study is being conducted at the Cancer Center of the University of Pennsylvania by Dr. Joseph Treat and studies the effects of LED in several types of solid tumors including breast, lung, prostate, and leukemia in patients who have failed standard treatments.

NeoPharm's proprietary liposomes are designed to counteract the genetic Multiple Drug Resistance (MDR) problem which is so prevalent in cancer patients. Pre-clinical work has shown that NeoPharm's liposome blocks the function of p-glycoprotein which is...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (1997-06-30)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry